128 related articles for article (PubMed ID: 31464835)
1. Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis.
Calcanes G; Vacirca JL
J Infus Nurs; 2019; 42(5):260-263. PubMed ID: 31464835
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Navari RM
Expert Opin Drug Saf; 2020 Feb; 19(2):205-210. PubMed ID: 31709853
[No Abstract] [Full Text] [Related]
3. Safety Profile of HTX-019 Administered as an Intravenous Push in Cancer Patients: A Retrospective Review.
Walton GD
Adv Ther; 2019 Mar; 36(3):662-669. PubMed ID: 30706408
[TBL] [Abstract][Full Text] [Related]
4. HTX-019 via 2-min injection or 30-min infusion in healthy subjects.
Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
Future Oncol; 2019 Mar; 15(8):865-874. PubMed ID: 30574797
[TBL] [Abstract][Full Text] [Related]
5. Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.
Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
Future Oncol; 2018 Nov; 14(27):2849-2859. PubMed ID: 29873529
[TBL] [Abstract][Full Text] [Related]
6. Safety of antiemetic prophylaxis with HTX-019 as a 30-min infusion in patients with cancer: a retrospective study.
Perry TS; Dickson N; Patton JF
Future Oncol; 2020 Mar; 16(7):263-268. PubMed ID: 31984777
[No Abstract] [Full Text] [Related]
7. IV aprepitant (Cinvanti) for chemotherapy-induced nausea and vomiting.
Med Lett Drugs Ther; 2018 Dec; 60(1561):e200-e201. PubMed ID: 30653479
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
9. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
10. Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.
Pendergrass K; Hargreaves R; Petty KJ; Carides AD; Evans JK; Horgan KJ
Drugs Today (Barc); 2004 Oct; 40(10):853-63. PubMed ID: 15605119
[TBL] [Abstract][Full Text] [Related]
11. HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis.
Navari RM
Future Oncol; 2019 Jan; 15(3):241-255. PubMed ID: 30304952
[TBL] [Abstract][Full Text] [Related]
12. The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy.
Navari RM
Expert Opin Drug Saf; 2019 Dec; 18(12):1127-1132. PubMed ID: 31622113
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
Kim JE; Jang JS; Kim JW; Sung YL; Cho CH; Lee MA; Kim DJ; Ahn MJ; Lee KY; Sym SJ; Lim MC; Jung H; Cho EK; Min KW
Support Care Cancer; 2017 Mar; 25(3):801-809. PubMed ID: 27826874
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
[TBL] [Abstract][Full Text] [Related]
15. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
Bakhshi S; Batra A; Biswas B; Dhawan D; Paul R; Sreenivas V
Support Care Cancer; 2015 Nov; 23(11):3229-37. PubMed ID: 25851802
[TBL] [Abstract][Full Text] [Related]
16. Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy.
Navari RM; Mosier MC
Onco Targets Ther; 2019; 12():3277-3284. PubMed ID: 31118678
[No Abstract] [Full Text] [Related]
17. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.
Ottoboni T; Keller MR; Cravets M; Clendeninn N; Quart B
Drug Des Devel Ther; 2018; 12():429-435. PubMed ID: 29535504
[TBL] [Abstract][Full Text] [Related]
18. Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.
Molassiotis A; Nguyen AM; Rittenberg CN; Makalinao A; Carides A
Future Oncol; 2013 Oct; 9(10):1443-50. PubMed ID: 23987791
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
20. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
